mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

This study is testing whether combining mFOLFOX7 chemotherapy with camrelizumab (an immunotherapy) and apatinib (a targeted anti-cancer drug) works as a first-line treatment for people with advanced liver cancer (HCC) that is at stage III. This is a more intensive combination approach than standard treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with stage III primary liver cancer (HCC) according to Chinese liver cancer staging - You have not yet received any first-line drug treatment (such as sorafenib) - You have at least one measurable tumor on imaging - Your liver function is Grade A or B (Child-Pugh scale) **You may NOT be eligible if...** - You have already started first-line treatment - Your cancer has spread beyond the liver to distant organs - Your liver or overall health is too poor to tolerate chemotherapy Talk to your doctor to see if this trial is right for you.